Amgen Inc. (AMGN) Hits New 1-Year High at $176.64
Amgen Inc. (NASDAQ:AMGN) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $176.64 and last traded at $175.45, with a volume of 2,004,648 shares traded. The stock had previously closed at $174.31.
Several brokerages recently issued reports on AMGN. Jefferies Group raised their target price on shares of Amgen from $187.00 to $198.00 and gave the stock a “buy” rating in a report on Thursday, July 28th. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $166.00 target price on the stock in a report on Wednesday, June 29th. Vetr upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $159.50 target price on the stock in a report on Monday, June 13th. Morgan Stanley restated a “buy” rating and issued a $195.00 target price on shares of Amgen in a report on Friday, April 29th. Finally, Leerink Swann restated a “hold” rating on shares of Amgen in a report on Sunday, June 26th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $184.92.
The stock has a market capitalization of $130.81 billion and a PE ratio of 17.89. The company has a 50-day moving average price of $166.01 and a 200-day moving average price of $155.55.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.74 by $0.10. During the same period last year, the company posted $2.57 earnings per share. The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. The business’s quarterly revenue was up 5.9% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post $11.37 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 8th. Investors of record on Wednesday, August 17th will be issued a dividend of $1.00 per share. This represents a $4.00 dividend on an annualized basis and a yield of 2.29%. The ex-dividend date of this dividend is Monday, August 15th.
In related news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
A number of institutional investors recently bought and sold shares of AMGN. Schwab Charles Investment Management Inc. increased its position in Amgen by 0.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 3,247,019 shares of the medical research company’s stock valued at $527,089,000 after buying an additional 11,041 shares during the last quarter. PVG Asset Management bought a new position in Amgen during the fourth quarter valued at about $2,712,000. BlackRock Investment Management LLC increased its position in Amgen by 3.7% in the fourth quarter. BlackRock Investment Management LLC now owns 2,492,571 shares of the medical research company’s stock valued at $404,619,000 after buying an additional 87,862 shares during the last quarter. BlackRock Advisors LLC increased its position in Amgen by 40.1% in the fourth quarter. BlackRock Advisors LLC now owns 3,746,237 shares of the medical research company’s stock valued at $608,126,000 after buying an additional 1,071,485 shares during the last quarter. Finally, TrimTabs Asset Management LLC increased its position in Amgen by 1.9% in the fourth quarter. TrimTabs Asset Management LLC now owns 14,887 shares of the medical research company’s stock valued at $2,417,000 after buying an additional 274 shares during the last quarter.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.